quinoxalines has been researched along with Addiction, Opioid in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butt, ZA | 1 |
| Asatryan, A; Geoffroy, P; Kort, J; Kosloski, MP; Liu, W; Zhao, W | 1 |
| Arnsten, JH; Litwin, AH; Nahvi, S; Segal, KS | 1 |
| Hooten, WM; Warner, DO | 1 |
| Warparkowski, A | 1 |
| Altice, F; Barr, E; Chen, E; Conway, B; Dalgard, O; Dore, GJ; Dutko, FJ; Gane, EJ; Gendrano, IN; Grebely, J; Howe, AY; Huang, HC; Litwin, AH; Luetkemeyer, A; Nahass, R; Nguyen, BY; Nickle, DC; Peng, CY; Platt, HL; Robertson, MN; Shibolet, O; Wahl, J | 1 |
| Arnsten, JH; Bernstein, SL; Nahvi, S; Richter, KP; Wu, B | 1 |
| Aase, DM; Atkinson, DM; Gewirtz, JC; Harris, AC | 1 |
| Hall, SR; Jhamandas, K; Milne, B; Sullivan, ME | 1 |
| García-Sevilla, JA; González-Maeso, J; Guimón, J; Meana, JJ | 1 |
5 trial(s) available for quinoxalines and Addiction, Opioid
| Article | Year |
|---|---|
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Methadone; Middle Aged; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Young Adult | 2017 |
Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics.
Topics: Adult; Benzazepines; Cross-Sectional Studies; Directly Observed Therapy; Female; Follow-Up Studies; Humans; Male; Methadone; New York City; Opioid-Related Disorders; Pilot Projects; Quinoxalines; Research Design; Self Administration; Smoking; Smoking Cessation; Substance Abuse Treatment Centers; Varenicline | 2014 |
Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial.
Topics: Adult; Analgesics, Opioid; Benzazepines; Chronic Pain; Depression; Feasibility Studies; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Opioid-Related Disorders; Pain Measurement; Pilot Projects; Quinoxalines; Single-Blind Method; Substance Withdrawal Syndrome; Treatment Outcome; Varenicline | 2015 |
[High chance of healing for opiate dependent patients].
Topics: Amides; Benzofurans; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Medication Adherence; Opiate Substitution Treatment; Opioid-Related Disorders; Quinoxalines; Substance Abuse, Intravenous; Sulfonamides | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Medication Adherence; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Quinoxalines; Recurrence; Substance Abuse, Intravenous; Young Adult | 2016 |
5 other study(ies) available for quinoxalines and Addiction, Opioid
| Article | Year |
|---|---|
Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder.
Topics: Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Opioid-Related Disorders; Quinoxalines; Sulfonamides | 2022 |
Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.
Topics: Benzazepines; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Female; Humans; Longitudinal Studies; Male; Mental Disorders; Methadone; Middle Aged; Narcotics; Nicotinic Agonists; Opioid-Related Disorders; Prevalence; Primary Health Care; Quinoxalines; Smoking; Smoking Cessation; Socioeconomic Factors; Treatment Outcome; Varenicline | 2013 |
Double dissociation in the neural substrates of acute opiate dependence as measured by withdrawal-potentiated startle.
Topics: Acoustic Stimulation; Amygdala; Analysis of Variance; Animals; Behavior, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Fear; Male; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Nucleus Accumbens; Opioid-Related Disorders; Quinoxalines; Rats; Rats, Sprague-Dawley; Reflex, Startle | 2006 |
Suppression of acute and chronic opioid withdrawal by a selective soluble guanylyl cyclase inhibitor.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Cyclic GMP; Enzyme Inhibitors; Excitatory Amino Acids; Guanylate Cyclase; Locus Coeruleus; Male; Morphine; Naloxone; Narcotic Antagonists; Opioid-Related Disorders; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome | 2000 |
mu-opioid receptor and alpha2-adrenoceptor agonist stimulation of [35S]GTPgammaS binding to G-proteins in postmortem brains of opioid addicts.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Autopsy; Brain; Brimonidine Tartrate; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Male; Opioid-Related Disorders; Postmortem Changes; Quinoxalines; Receptors, Opioid, mu; Reference Values; Sulfur Radioisotopes | 2000 |